AstraZeneca PLC (AZNCF)
130.24
+1.04
(+0.80%)
USD |
OTCM |
Nov 14, 16:00
AstraZeneca EPS Diluted (Quarterly): 1.24 for June 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 1.24 |
March 31, 2024 | 1.40 |
December 31, 2023 | 0.62 |
September 30, 2023 | 0.88 |
June 30, 2023 | 1.17 |
March 31, 2023 | 1.16 |
December 31, 2022 | 0.58 |
September 30, 2022 | 1.05 |
June 30, 2022 | 0.23 |
March 31, 2022 | 0.25 |
December 31, 2021 | -0.22 |
September 30, 2021 | -1.10 |
June 30, 2021 | 0.42 |
March 31, 2021 | 1.18 |
December 31, 2020 | 0.78 |
September 30, 2020 | 0.49 |
June 30, 2020 | 0.58 |
March 31, 2020 | 0.59 |
December 31, 2019 | 0.24 |
September 30, 2019 | 0.23 |
June 30, 2019 | 0.09 |
March 31, 2019 | 0.47 |
December 31, 2018 | 0.82 |
September 30, 2018 | 0.34 |
June 30, 2018 | 0.27 |
Date | Value |
---|---|
March 31, 2018 | 0.27 |
December 31, 2017 | 1.03 |
September 30, 2017 | 0.54 |
June 30, 2017 | 0.38 |
March 31, 2017 | 0.42 |
December 31, 2016 | 1.45 |
September 30, 2016 | 0.80 |
June 30, 2016 | -0.0024 |
March 31, 2016 | 0.51 |
December 31, 2015 | 0.63 |
September 30, 2015 | 0.60 |
June 30, 2015 | 0.55 |
March 31, 2015 | 0.44 |
December 31, 2014 | -0.25 |
September 30, 2014 | 0.20 |
June 30, 2014 | 0.63 |
March 31, 2014 | 0.40 |
December 31, 2013 | -0.42 |
September 30, 2013 | 0.99 |
June 30, 2013 | 0.66 |
March 31, 2013 | 0.81 |
December 31, 2012 | 1.22 |
September 30, 2012 | 1.20 |
June 30, 2012 | 1.26 |
March 31, 2012 | 1.27 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-1.10
Minimum
Sep 2021
1.40
Maximum
Mar 2024
0.6074
Average
0.59
Median
Mar 2020
EPS Diluted (Quarterly) Benchmarks
Adaptimmune Therapeutics PLC | 0.24 |
Biodexa Pharmaceuticals PLC | -- |
Verona Pharma PLC | -0.56 |
NuCana PLC | -3.785 |
Autolus Therapeutics PLC | -0.22 |
EPS Diluted (Quarterly) Related Metrics
Net Income (Quarterly) | 1.927B |
Revenue (Quarterly) | 12.94B |
Total Expenses (Quarterly) | 10.19B |
Enterprise Value | 227.21B |
Gross Profit Margin (Quarterly) | 83.13% |
Profit Margin (Quarterly) | 14.89% |
Earnings Yield | 3.18% |
Operating Earnings Yield | 4.83% |
Normalized Earnings Yield | 3.468 |